Abstract
ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 949-953 |
| Number of pages | 5 |
| Journal | Transplantation proceedings |
| Volume | 18 |
| Issue number | 4 |
| State | Published - 1986 |
ASJC Scopus subject areas
- Surgery
- Transplantation